TY - JOUR
T1 - Mass screening for neuroblastoma at 6 months of age
T2 - Difficult to justify
AU - Suita, S.
AU - Tajiri, T.
AU - Akazawa, K.
AU - Sera, Y.
AU - Takamatsu, H.
AU - Mizote, H.
AU - Ohgami, H.
AU - Kurosaki, N.
AU - Hara, T.
AU - Okamura, J.
AU - Miyazaki, S.
AU - Sugimoto, T.
AU - Kawakami, K.
AU - Tsuneyoshi, M.
AU - Tasaka, H.
AU - Yano, H.
AU - Akiyama, H.
AU - Ikeda, K.
N1 - Funding Information:
From the Departments of Pediatric Surgery, Pediatrics, Pathology, and Medical Informatics, Kyushu University; the Department of Pediatric Surgery, Kumamoto University; the Departments of Pediatric Surgery and Pediatrics, Kagoshima University; the Department of Pediatric Surgery, Kurume University; the Departments of Surgery, Fukuoko Children’s Hospital: the Department of Surgery, Nagasaki University; the Devision of Pediatrics, National Kyushu Cancer Center; the Department of Pediatrics, Saga Medical School; the Department of Pediatrics, Miyazaki Medical College. Japan. Presented at the 31st Annual Meeting of the Pact& Association Pediatric Surgeons, Maui, Hawaii, June 9-13, 199%. Supported by Grants-in-Aid from the Children’s Cancer Association of Japan. Address reprint requests to Sachiyo Suita, MD, PhD, Department of Pediatric Surgery, Faculty of Medicine, Kyushu University, 3-l-l Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Copyright o 1998 by WB. Saunders Company 0022-3468/983311-0022$03.00/O
PY - 1998/11
Y1 - 1998/11
N2 - Background/Purpose: A statistical analysis of the mass screening for neuroblastoma in Japan based on a population study rarely has been reported. This study aims to evaluate retrospectively the effectiveness of mass screening at 6 months of age using the available population data. Methods: The data on the neuroblastoma cases registered by the Committee for Pediatric Solid Malignant Tumors in the Kyushu area were analyzed based on both screened and unscreened populations in the Kyushu area. Results: From 1988 to 1992, the cumulative incidence of neuroblastoma in children less than 5 years of age was 82 in 484,599 for screened children, and 11 in 92,966 for unscreened children, respectively. Fourteen of the 82 screened patients had negative findings at 6 months of age (MS-negative cases). No significant difference was observed in the cumulative mortality rates from neuroblastoma in children younger than 5 years of age between the screened children and the unscreened children. Six of seven patients who died among the screened children were MS-negative cases with stage III or IV disease. In addition, no significant difference was found in the cumulative mortality rates from the neuroblastoma cases in patients less than 5 years of age between the children screened from 1988 to 1992 (7 of 484,599) and all children from 1980 to 1984 (14 of 668,084). Conclusions: These findings suggests that the majority of the patients detected by mass screening had a favorable prognosis, and, mass screening in Japan for children less than 6 months of age was not observed to reduce the incidence and mortality from neuroblastoma. Therefore, mass screening at 6 months of age was not found to improve substantially the prognosis of patients with unfavorable neuroblastoma identified over 1 year of age, which is the primary purpose of such mass screening for neuroblastoma.
AB - Background/Purpose: A statistical analysis of the mass screening for neuroblastoma in Japan based on a population study rarely has been reported. This study aims to evaluate retrospectively the effectiveness of mass screening at 6 months of age using the available population data. Methods: The data on the neuroblastoma cases registered by the Committee for Pediatric Solid Malignant Tumors in the Kyushu area were analyzed based on both screened and unscreened populations in the Kyushu area. Results: From 1988 to 1992, the cumulative incidence of neuroblastoma in children less than 5 years of age was 82 in 484,599 for screened children, and 11 in 92,966 for unscreened children, respectively. Fourteen of the 82 screened patients had negative findings at 6 months of age (MS-negative cases). No significant difference was observed in the cumulative mortality rates from neuroblastoma in children younger than 5 years of age between the screened children and the unscreened children. Six of seven patients who died among the screened children were MS-negative cases with stage III or IV disease. In addition, no significant difference was found in the cumulative mortality rates from the neuroblastoma cases in patients less than 5 years of age between the children screened from 1988 to 1992 (7 of 484,599) and all children from 1980 to 1984 (14 of 668,084). Conclusions: These findings suggests that the majority of the patients detected by mass screening had a favorable prognosis, and, mass screening in Japan for children less than 6 months of age was not observed to reduce the incidence and mortality from neuroblastoma. Therefore, mass screening at 6 months of age was not found to improve substantially the prognosis of patients with unfavorable neuroblastoma identified over 1 year of age, which is the primary purpose of such mass screening for neuroblastoma.
UR - http://www.scopus.com/inward/record.url?scp=13144276353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13144276353&partnerID=8YFLogxK
U2 - 10.1016/S0022-3468(98)90607-8
DO - 10.1016/S0022-3468(98)90607-8
M3 - Article
C2 - 9856893
AN - SCOPUS:13144276353
VL - 33
SP - 1674
EP - 1678
JO - Journal of Pediatric Surgery
JF - Journal of Pediatric Surgery
SN - 0022-3468
IS - 11
ER -